Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections (IGNITE3)

• Sponsor: Tetraphase Pharmaceuticals, Inc.
• Information provided by (Responsible Party): Tetraphase Pharmaceuticals, Inc.

Study Description

Brief Summary:

The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of eravacycline compared to ertapenem in treating participants with complicated urinary tract infections (cUTI).

Condition or disease	Intervention/treatment	Phase
Complicated Urinary Tract Infections	Drug: Eravacycline; Drug: Ertapenem; Drug: Placebo; Drug: Levofloxacin	Phase 3

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	1200 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:	Treatment
Official Title:	A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections
Actual Study Start Date :	January 2017
Actual Primary Completion Date :	December 2017
Actual Study Completion Date :	January 2018

Arms and Interventions

Arm	Intervention/treatment
Experimental: Eravacycline (Intravenous)/Levofloxacin (Oral)	Drug: Eravacycline; Other Name: TP-434; Drug: Placebo; Drug: Levofloxacin; Other Name: Levaquin
Active Comparator: Ertapenem (Intravenous)/Levofloxacin (Oral)	Drug: Ertapenem; Other Name: Invanz; Drug: Placebo; Drug: Levofloxacin; Other Name: Levaquin

Outcome Measures

Primary Outcome Measures :

1. Proportion of Participants in the microbiological Intent-to-treat (micro-ITT) Population Demonstrating Clinical Cure and Microbiologic Success at the End of Intravenous (EOI) Visit [ Time Frame: EOI visit (within 1 day of the completion of intravenous study drug treatment) ]
2. Proportion of Participants in the micro-ITT Population Demonstrating Clinical Cure and Microbiologic Success at the Test-Of-Cure (TOC) Visit [ Time Frame: TOC visit (14-17 days after randomization) ]

Secondary Outcome Measures :

1. Proportion of Participants in the microbiological Modified Intent-To-Treat (micro-MITT) Population and the Microbiologically Evaluable (ME) Population Demonstrating Microbiologic Success at the TOC Visit [ Time Frame: TOC visit (14-17 days after randomization) ]

Eligibility Criteria

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

1. Male or female participant with either:

   1. Pyelonephritis and normal urinary tract anatomy (approximately 50% of the total population), or

   2. cUTI with at least one of the following conditions associated with a risk for developing cUTI:

      • Indwelling urinary catheter
      • Urinary retention (at least approximately 100 milliliters (mL) of residual urine after voiding)
      • History of neurogenic bladder
      • Partial obstructive uropathy (for example, nephrolithiasis, bladder stones, and ureteral strictures)
      • Azotemia of renal origin (not congestive heart failure [CHF] or volume related) such that the serum blood urea nitrogen [BUN] is elevated (>20 milligrams [mg]/deciliters [dL]) and the serum BUN:creatinine ratio is <15
      • Surgically modified or abnormal urinary tract anatomy (for example, bladder diverticula, redundant urine collection system) except urinary tract surgery within the last 30 days (placing of stents or catheters is not considered to be surgical modification)
2. At least 18 years of age at time of consent
3. Able to provide informed consent

4. At least two of the following signs or symptoms:

   1. Chills, rigors, or warmth associated with fever or hypothermia
   2. Flank pain (pyelonephritis) or pelvic pain (cUTI)
   3. Nausea or vomiting
   4. Dysuria, urinary frequency, or urinary urgency
   5. Costo-vertebral angle tenderness on physical examination

5. Urine specimen with evidence of pyuria

   1. Dipstick analysis positive for leukocyte esterase (where positive result is at least "++" as indicated on the urine dipstick provided in the laboratory kit), or
   2. ≥10 white blood cells (WBCs) per cubic millimeter, or
   3. ≥10 WBCs per high power field
6. If male: must agree to use an effective barrier method of contraception (for example, condom) during the study and for 14 days following the last dose if sexually active with a female of childbearing potential
7. If female, not pregnant or nursing or, if of childbearing potential: must commit to either use at least two medically accepted, effective methods of birth control (for example, condom, spermicidal gel, oral contraceptive, indwelling intrauterine device, hormonal implant /patch, injections, approved cervical ring) during study drug dosing and for 14 days following last study drug dose or practicing sexual abstinence

Exclusion Criteria:

1. Use of systemic antibiotics effective in cUTI within 72 hours prior to enrollment except under the following circumstances:

   1. Participants with suspected acute cUTI who have received a single dose of effective non-study antibiotics for the acute cUTI
   2. Signs and symptoms of cUTI developed while on the antibiotic for another indication
2. History of an ertapenem-resistant urinary tract infection within 1 year of enrollment
3. Likely to require >10 days of antibiotic treatment to cure the acute cUTI or likely to receive ongoing antibacterial drug prophylaxis prior to the Follow Up visit (21-28 days after randomization) [for example, participants with chronic vesiculo-ureteral reflux]
4. Unlikely to survive at least through the duration of the study
5. Hypotension, systolic blood pressure ≤90 millimeters of mercury [mmHg]
6. Complicated pyelonephritis with complete obstruction or known or suspected renal or perinephric abscess, emphysematous pyelonephritis, or Any condition likely to require surgery to achieve cure (this does not include procedure to place catheters or obtain diagnosis)
7. Known or suspected urinary fungal infection
8. Uncomplicated lower urinary tract infections
9. Suspected or confirmed active prostatitis, or currently under treatment for prostatitis
10. High risk for cUTI due to Pseudomonas (for example, history of prior cUTIs due to Pseudomonas, ≥20 mg once a day prednisone or equivalent steroid, and other risk factors as perceived by the Investigator)
11. History of renal transplantation
12. Presence of an ileal loop
13. Any history of trauma to the pelvis or urinary tract occurring within 30 days of screening
14. Indwelling urinary catheters present at screening which are not expected to be removed or replaced within 72 hours of enrollment (for example, nephrostomy tubes, stents, urethral and suprapubic catheters).
15. Known concomitant human immunodeficiency virus (HIV) infection with CD4 counts below 200 within the last six months, or an acquired immune deficiency syndrome (AIDS) defining diagnosis within the last six months
16. Neutropenia (Absolute neutrophil count <1,000 polymorphonuclear leukocytes [PMNs]/microliters [µL])
17. Participation in a study with an experimental drug or device within 30 days prior to enrollment
18. Known or suspected hypersensitivity to tetracyclines, carbapenems, or β-lactams
19. History of seizures
20. Any other unstable or clinically significant concurrent medical condition (for example, immunosuppressive therapy, chemotherapy, class IV heart or lung disease, end stage renal disease, or requiring hemodialysis) that would, in the opinion of the Investigator, jeopardize the safety of a participant and/or their compliance with the protocol

Contacts and Locations

  Show 72 Study Locations

Sponsors and Collaborators

Tetraphase Pharmaceuticals, Inc.

Investigators

Layout table for investigator information

Study Director:	Chief Medical Officer	Tetraphase Pharmaceuticals

More Information

Layout table for additonal information

Responsible Party:	Tetraphase Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:	NCT03032510 History of Changes
Other Study ID Numbers:	TP-434-021
First Posted:	January 26, 2017
Last Update Posted:	April 11, 2018
Last Verified:	September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:		Yes
Studies a U.S. FDA-regulated Device Product:		No

Additional relevant MeSH terms:

Layout table for MeSH terms

Infection; Communicable Diseases; Urinary Tract Infections; Urologic Diseases; Levofloxacin; Ofloxacin; Ertapenem; Anti-Infective Agents, Urinary; Anti-Infective Agents	Renal Agents; Anti-Bacterial Agents; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 Enzyme Inhibitors